Researchers are forever seeking to outsmart therapy-resistant cancers. "No Through Road," a feature published Aug. 5 in Cancer Today, a publication of the American Association for Cancer Research, highlights just this quest.

When Peoria, Illinois-based OSF HealthCare transitioned from analog to digital imaging, one aspect of the radiology continuum proved challenging: quality assurance. “We had a fairly robust, paper-based QA process when we were film and paper,” recalls Tom Cox, director of radiology at OSF Saint Francis Medical Center (SFMC). “When we went to PACS and went paperless, however, we virtually stopped getting feedback from the radiologists on quality. We knew we needed something to replace the paper process.”

Radiologists and hospital administrators are finding common ground when it comes to one significant conundrum, according to Richard Duszak, MD, CEO of the ACR’s Harvey Neiman Health Policy Institute. “We are moving from a system where we got paid for doing procedures to one where we will get paid for taking care of patients,” Duszak said in a presentation at the 2013 conference of AHRA: The Association for Medical Imaging Management, held July 28-31 in Minneapolis, Minnesota. “The big word is value, and it’s going to be a real challenge for physicians and hospital administrators.”

Siemens Healthcare has launched its new Biograph mCT Flow – a groundbreaking PET-CT system. For the first time ever the system overcomes the limitations of conventional bed-based PET-CT with FlowMotion, an innovative new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data.

Navidea Biopharmaceuticals announces award of a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the National Institutes of Health (NIH) in connection with the Company's Phase 3 clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer’s disease.

Navidea has signed an agreement with Siemens’ PETNET Solutions that grants PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694, an investigational beta-amyloid PET imaging agent, which is currently being evaluated in Phase 2 and 3 clinical trials evaluating subjects with signs or symptoms of cognitive impairment such as Mild Cognitive Impairment and Alzheimer’s disease.

Regadenoson stress Rb-82 PET/CT myocardial perfusion imaging (MPI) is highly sensitive, 92 percent, for the detection of obstructive CAD and beats SPECT MPI, according to a study published online Aug. 12 in the Journal of Nuclear Medicine.

Flame retardants mimic estradiols in the body, potentially causing havoc on natural endocrine homeostasis, according to new 3D x-ray crystallography research published online Aug. 19 in Environmental Health Perspectives.